Ahmed Dahshan , Hala Rashad El Habashy , Shahenda Al Menabbawy , Alaa Ahmed Shalan , Noha El Sawy
{"title":"Electric vs. magnetic: Which brain stimulation wins for bothering symptoms in multiple sclerosis?","authors":"Ahmed Dahshan , Hala Rashad El Habashy , Shahenda Al Menabbawy , Alaa Ahmed Shalan , Noha El Sawy","doi":"10.1016/j.msard.2025.106365","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Multiple sclerosis (MS) is a chronic disease marked by fatigue, pain, cognitive impairment, and mood disorders. Pharmacological treatments often provide limited relief and have side effects, prompting interest in non-invasive neuromodulation techniques like transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). We aimed to compare the short-term efficacy of tDCS and TMS in alleviating fatigue, pain, depression, and cognitive impairment in MS patients.</div></div><div><h3>Methods</h3><div>In a randomized, single-blinded, three-arm trial, 30 patients with relapsingremitting MS were assigned to active tDCS, active TMS, or placebo. The tDCS group received 2 mA anodal stimulation over the motor cortex for 20 min daily for five days, while the TMS group received 10 Hz stimulation at 80 % of the resting motor threshold for the same duration. The placebo group received sham stimulation. Outcomes were assessed using the Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, Beck Depression Inventory (BDI), and Brief International Cognitive Assessment for MS (BICAMS).</div></div><div><h3>Results</h3><div>Both tDCS and TMS groups showed significant improvements in fatigue, pain, and depression compared to placebo (<em>p</em> < 0.05). No significant cognitive changes were observed in any group.</div></div><div><h3>Conclusion</h3><div>Short-term tDCS and TMS are effective for reducing fatigue, pain, and depression in MS patients, with tDCS showing potential for home use and TMS for clinical settings. Cognitive improvements may require longer treatment durations or combined therapies.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"96 ","pages":"Article 106365"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034825001087","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Multiple sclerosis (MS) is a chronic disease marked by fatigue, pain, cognitive impairment, and mood disorders. Pharmacological treatments often provide limited relief and have side effects, prompting interest in non-invasive neuromodulation techniques like transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). We aimed to compare the short-term efficacy of tDCS and TMS in alleviating fatigue, pain, depression, and cognitive impairment in MS patients.
Methods
In a randomized, single-blinded, three-arm trial, 30 patients with relapsingremitting MS were assigned to active tDCS, active TMS, or placebo. The tDCS group received 2 mA anodal stimulation over the motor cortex for 20 min daily for five days, while the TMS group received 10 Hz stimulation at 80 % of the resting motor threshold for the same duration. The placebo group received sham stimulation. Outcomes were assessed using the Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, Beck Depression Inventory (BDI), and Brief International Cognitive Assessment for MS (BICAMS).
Results
Both tDCS and TMS groups showed significant improvements in fatigue, pain, and depression compared to placebo (p < 0.05). No significant cognitive changes were observed in any group.
Conclusion
Short-term tDCS and TMS are effective for reducing fatigue, pain, and depression in MS patients, with tDCS showing potential for home use and TMS for clinical settings. Cognitive improvements may require longer treatment durations or combined therapies.
期刊介绍:
Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource.
A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.